• 1
    Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 27152729.
  • 2
    Morris PJ. Transplantation–a medical miracle of the 20th century. N Engl J Med 2004; 351: 26782680.
  • 3
    Sayegh MH, Carpenter CB. Transplantation 50 years later–progress, challenges, and promises. N Engl J Med 2004; 351: 27612766.
  • 4
    Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605612.
  • 5
    Hariharan S, McBride MA, Cherikh WS et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311318.
  • 6
    Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580590.
  • 7
    Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931940.
  • 8
    Myers BD, Ross J, Newton L et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699705.
  • 9
    Myers BD, Sibley R, Newton L et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590600.
  • 10
    Berth-Jones J. The use of ciclosporin in psoriasis. J Dermatolog Treat 2005; 16: 258277.
  • 11
    Colvin RB. Chronic allograft nephropathy. N Engl J Med 2003; 349: 22882290.
  • 12
    Williams D, Haragsim L. Calcineurin nephrotoxicity. Adv Chronic Kidney Dis 2006; 13: 4755.
  • 13
    Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 23262333.
  • 14
    Pascual M, Swinford RD, Ingelfinger JR et al. Chronic rejection and chronic cyclosporin toxicity in renal allografts. Immunol Today 1998; 19: 514519.
  • 15
    Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 10831091.
  • 16
    Neumayer HH. Introducing everolimus (Certican) in organ transplantation: An overview of preclinical and early clinical developments. Transplantation 2005; 79: S72S75.
  • 17
    Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194202.
  • 18
    McAlister VC, Gao Z, Peltekian K et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355: 376377.
  • 19
    Gonwa T, Mendez R, Yang HC et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months. Transplantation 2003; 75: 12131220.
  • 20
    Mendez R, Gonwa T, Yang HC et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005; 80: 303309.
  • 21
    Johnson RW, Kreis H, Oberbauer R et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777786.
  • 22
    Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809817.
  • 23
    Peddi VR, Jensik S, Pescovitz M et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005; 19: 130136.
  • 24
    Sennesael JJ, Bosmans JL, Bogers JP et al. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005; 80: 15781585.
  • 25
    Diekmann F, Budde K, Oppenheimer F et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 18691875.
  • 26
    Watson CJ, Firth J, Williams PF et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5: 24962503.
  • 27
    Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461470.
  • 28
    Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378383.
  • 29
    Benigni A, Bruzzi I, Mister M et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int 1999; 55: 674685.
  • 30
    Bennett WM, DeMattos A, Meyer MM et al. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 10891100.
  • 31
    Sommerer C, Hergesell O, Nahm AM et al. Cyclosporin A toxicity of the renal allograft—A late complication and potentially reversible. Nephron 2002; 92: 339345.
  • 32
    Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 15671573.
  • 33
    Magee C, Pascual M. The growing problem of chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 994996.
  • 34
    Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 19101917.
  • 35
    Weir MR, Blahut S, Drachenburg C et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24: 379386.
  • 36
    Bakker RC, Hollander AA, Mallat MJ et al. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003; 64: 10271034.
  • 37
    Mourad G, Vela C, Ribstein J, Mimran A. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 1998; 65: 661667.
  • 38
    Stoves J, Newstead CG, Baczkowski AJ et al. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19: 21132120.
  • 39
    Ducloux D, Fournier V, Bresson-Vautrin C et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: A preliminary report. Transplantation 1998; 65: 15041506.
  • 40
    Dudley C, Pohanka E, Riad H et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The “creeping creatinine” study. Transplantation 2005; 79: 466475.
  • 41
    Hollander AA, Van Saase JL, Kootte AM et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610614.
  • 42
    Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: Benefits and risks. Nephrol Dial Transplant 2006; 21: 562568.
  • 43
    Padi SS, Chopra K. Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol Res 2002; 45: 413420.
  • 44
    Castello L, Sainaghi PP, Bergamasco L et al. Pathways of glomerular toxicity of cyclosporine-A: An “in vitro” study. J Physiol Pharmacol 2005; 56: 649660.
  • 45
    Stallone G, Infante B, Schena A et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 37553762.
  • 46
    Morrisett JD, Bdel-Fattah G, Hoogeveen R et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 11701180.
  • 47
    Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005; 353: 20882089.
  • 48
    Banfi G, Villa M, Cresseri D, Ponticelli C. The clinical impact of chronic transplant glomerulopathy in cyclosporine era. Transplantation 2005; 80: 13921397.
  • 49
    Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905913.
  • 50
    Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222230.
  • 51
    Greene T. Are observational studies ‘just as effective’ as randomized clinical trials? Blood Purif 2000; 18: 317322.
  • 52
    Wolfe RA. Observational studies are just as effective as randomized clinical trials. Blood Purif 2000; 18: 323326.
  • 53
    Vlahakes GJ. The value of phase 4 clinical testing. N Engl J Med 2006; 354: 413415.